Drug intelligence / Profile preview

CC-486 + durvalumab

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

CC-486 + durvalumab is a combination therapy consisting of oral azacitidine (CC-486) and durvalumab. CC-486 is an oral DNA hypomethylating agent that modifies DNA to promote normal cell growth or cell death. Durvalumab is a monoclonal antibody that blocks programmed cell death ligand-1 (PD-L1), potentially allowing the immune system to better detect and eliminate cancer cells. The combination was designed to enhance immune response against immunologically \"cold\" solid tumors by combining epigenetic modification with immune checkpoint inhibition.

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on CC-486 + durvalumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-486 + durvalumab.